[Question] why does the satiety feel qualitatively different

Trying to get a straight answer on this: why does the satiety feel qualitatively different.

Reading the trial literature on this without misleading yourself.

Separate the monotherapy arms from the combination arms before you do anything else. They report different effect sizes and different tolerability, and almost every summary that circulates blends them.

Then read the tolerability tables rather than the headline. In combination work the interesting question is whether adding a second mechanism adds effect without adding proportionate side effects, and that question is answered in a table nobody quotes.

Finally, note the durations. Comparing a shorter readout here with a longer one from an established compound is not a comparison at all.

Why this compound is not simply another agonist, which is how it gets described everywhere else.

Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.

It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.

Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.

Would rather be corrected in public than confident in private.